Teleflex (NYSE: TFX) cuts 2026 sales view but lifts EPS guidance

Rhea-AI Filing Summary

Teleflex Incorporated reported second-quarter 2026 continuing-operations revenue of $570.3 million, up 28.9% year over year and up 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS from continuing operations was $0.96, down from $1.54, while adjusted diluted EPS edged up to $1.76 from $1.73, reflecting margin pressure but slightly higher underlying earnings.

The company completed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, estimating about $1.25 billion in after-tax proceeds and using this to pay off a $700 million term loan and support share repurchases. In the second quarter it repurchased 1.9 million shares for $250 million and plans a further $250 million accelerated share repurchase under a $1 billion authorization. Teleflex cut 2026 GAAP revenue growth guidance to 13.40%–14.40% and pro forma adjusted constant currency growth to 3.50%–4.50%, but raised adjusted EPS guidance to $6.90–$7.20, targeting about 19% adjusted operating margin. The company also highlighted innovation milestones, including FDA BLA approval of EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA, and continued clinical progress for its Freesolve resorbable magnesium scaffold platform.

Positive

• $570.3 million revenue from continuing operations in Q2 2026, up 28.9% year over year and 4.7% on a pro forma adjusted constant currency basis, indicating solid top-line expansion.
• Completed sale of the OEM business for $1.5 billion in cash, with estimated after-tax proceeds of about $1.25 billion to fund debt reduction and shareholder returns.
• Authorized $1 billion in share repurchases and executed $250 million in Q2 (1.9 million shares), with a further $250 million accelerated share repurchase planned and $750 million remaining authorization.
• Teleflex raised its 2026 adjusted diluted EPS guidance to $6.90–$7.20 and targets an adjusted operating margin of approximately 19% for continuing operations.
• Received FDA BLA approval for EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA, expanding the vascular and emergency medicine portfolio.

Negative

• Teleflex reduced its 2026 GAAP revenue growth outlook for continuing operations to 13.40%–14.40% and cut pro forma adjusted constant currency revenue growth guidance to 3.50%–4.50% amid slower-than-expected integration of the acquired Vascular Intervention business.
• Q2 2026 GAAP diluted EPS from continuing operations declined to $0.96 from $1.54, and adjusted operating margin fell to 19.6% from 24.8%, reflecting margin compression and higher operating expenses.
• Despite an 86.1% reported revenue increase, the Interventional segment posted a 1.0% decline in pro forma adjusted constant currency revenue growth in Q2 2026, highlighting integration and restructuring headwinds.

Filing Explained

The refinancing changed debt maturities, while the $250 million accelerated repurchase was announced for August 7 rather than completed in this filing.

This Form 8-K, which reports specified material events, furnishes Teleflex’s results for the quarter ended June 30, 2026 and its capital-allocation update. The disclosed refinancing is completed, while the planned accelerated share repurchase remains a future transaction; the immediate structural change is a replacement of debt instruments and maturities rather than a completed common-stock repurchase under that ASR.

Teleflex completed a $500 million private offering of 5.875% senior notes due 2032 and used the net proceeds, together with cash, to redeem all outstanding 4.625% notes due 2027. It also entered a new credit agreement providing a $1 billion revolving facility, a $500 million term A-1 facility, and a $700 million term A-2 facility.

A private placement is a sale of securities to selected investors outside a public offering; here, the disclosed securities are senior notes, so this financing adds debt rather than issuing common shares. At June 30, 2026, the balance sheet reported cash and cash equivalents of $300,159 thousand and long-term borrowings of $2,720,509 thousand.

The filing states that the $250 million accelerated share repurchase is intended to commence on August 7, 2026; a later disclosure would establish its completion and resulting share delivery or settlement.

8-K Event Classification

5 items: 1.8, 2.02, 2.2, 7.01, 9.01

5 items

Item 1.8 Item 1.8

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 2.2 Item 2.2

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 revenue from continuing operations: $570.3 million Q2 2026 GAAP diluted EPS from continuing operations: $0.96 Q2 2026 adjusted diluted EPS from continuing operations: $1.76 +4 more

7 metrics

Q2 2026 revenue from continuing operations $570.3 million Second quarter 2026; up 28.9% year over year and 4.7% on a pro forma adjusted constant currency basis

Q2 2026 GAAP diluted EPS from continuing operations $0.96 Compared to $1.54 in the prior-year quarter

Q2 2026 adjusted diluted EPS from continuing operations $1.76 Compared to $1.73 in the prior-year quarter

OEM business sale proceeds $1.5 billion Cash consideration from divestiture to Montagu and Kohlberg; about $1.25 billion estimated after-tax proceeds

Q2 2026 share repurchase $250 million Open-market repurchase of 1.9 million shares at an average price of $130.85 under $1 billion authorization

Term Loan A-2 payoff $700 million Debt associated with the Vascular Intervention acquisition repaid using OEM divestiture proceeds

2026 adjusted EPS guidance range $6.90–$7.20 Full-year 2026 adjusted diluted EPS from continuing operations; guidance increased from prior range

Key Terms

pro forma adjusted constant currency revenue growth, Accelerated Share Repurchase, European Union Medical Device Regulation, Italian payback measure, +1 more

5 terms

pro forma adjusted constant currency revenue growth financial

"up 4.7% on a pro forma adjusted constant currency basis1,2"

A non-GAAP revenue growth measure that shows how sales changed after removing or adjusting for one-time items, accounting effects, or assumed deal-related impacts (pro forma), and after converting figures to a fixed exchange-rate basis (constant currency). It aims to isolate underlying business sales performance by excluding temporary distortions and currency swings, so readers can compare period-to-period revenue as if exchange rates and special events had not affected the numbers.

Accelerated Share Repurchase financial

"Announces $250 Million Accelerated Share Repurchase Program"

An accelerated share repurchase is a deal where a company hires a bank to buy back a large block of its own stock immediately on the open market, with the bank later settling the exact number of shares over time. For investors it matters because the immediate reduction in shares outstanding can raise per‑share earnings and often supports the stock price, but it also uses company cash or borrowing and can change liquidity and future growth funding.

European Union Medical Device Regulation regulatory

"registration of medical devices under the European Union Medical Device Regulation"

A set of European rules that governs how medical devices are designed, tested, labeled and sold in the European Union; think of it as building codes for medical products that set safety and performance standards and require official review before devices reach patients. Investors care because these rules determine which products can be sold, how long approvals take, and how much companies must spend to comply—factors that affect revenue, timelines and risk.

Italian payback measure regulatory

"the items described in Italian payback measure"

A payback measure in Italy is a government rule that requires companies, often in healthcare and pharmaceuticals, to return part of their sales or profits when public spending or agreed budget limits are exceeded. Think of it like a retailer that must refund a portion of its receipts if a city-wide spending cap is breached; for investors it matters because it reduces net revenue, adds uncertainty to future cash flow and can change profit margins and valuation.

resorbable magnesium scaffold medical

"Freesolve™, a novel drug-eluting resorbable magnesium scaffold"

A resorbable magnesium scaffold is a temporary, tube-like medical implant made from a magnesium alloy that holds open a blocked blood vessel and then gradually dissolves and is absorbed by the body. Investors care because it promises the benefits of a traditional permanent stent while reducing long-term complications and repeat procedures, so its clinical performance, regulatory approval, and reimbursement determine market adoption and commercial value.

Earnings Snapshot

Revenue from continuing operations: $570.3 million · Guidance included

quarter ended June 30, 2026

Revenue from continuing operations $570.3 million up 28.9% year over year and up 4.7% on a pro forma adjusted constant currency basis

GAAP diluted EPS from continuing operations $0.96 down from $1.54 in the prior-year quarter

Adjusted diluted EPS from continuing operations $1.76 up from $1.73 in the prior-year quarter

2026 GAAP revenue growth guidance 13.40%–14.40% guidance range reduced versus prior outlook

2026 adjusted diluted EPS guidance $6.90–$7.20 guidance range increased versus prior outlook

Guidance

For full-year 2026, Teleflex targets 13.40%–14.40% GAAP revenue growth from continuing operations, 3.50%–4.50% pro forma adjusted constant currency revenue growth, and approximately 19% adjusted operating margin.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/06/2026 - 07:08 AM Accepted by SEC EDGAR 08/06/2026 - 07:08 AM Learn about SEC filing dates

FAQ

How did Teleflex (TFX) perform in Q2 2026 from continuing operations?

Teleflex generated $570.3 million in Q2 2026 revenue from continuing operations, up 28.9% year over year and 4.7% on a pro forma adjusted constant currency basis. GAAP diluted EPS was $0.96, while adjusted diluted EPS rose slightly to $1.76 from $1.73.

What full-year 2026 guidance did Teleflex (TFX) provide?

For 2026, Teleflex projects GAAP revenue growth from continuing operations of 13.40%–14.40% and pro forma adjusted constant currency revenue growth of 3.50%–4.50%. GAAP EPS guidance is $2.54–$2.84, and adjusted diluted EPS guidance increased to $6.90–$7.20 with about 19% adjusted operating margin.

What is Teleflex’s (TFX) capital allocation and share repurchase strategy?

Teleflex has a $1 billion share repurchase authorization and plans roughly $800 million of debt reduction funded mainly by Strategic Divestitures. In Q2 2026 it repurchased 1.9 million shares for $250 million and intends to launch a $250 million accelerated share repurchase.

What was the OEM divestiture and how will Teleflex (TFX) use the proceeds?

Teleflex completed the divestiture of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, estimating after-tax proceeds of about $1.25 billion. The company used these funds to pay off a $700 million Term Loan A-2 and support ongoing share repurchases.

Which new products and clinical programs did Teleflex (TFX) highlight?

Teleflex received FDA BLA approval for EZPLAZ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA. It also advanced its Freesolve resorbable magnesium scaffold program, reporting four-year BIOMAG-I data, completing BIOMAG-II enrollment, and initiating the U.S. BIOMAG-III pivotal trial.

How did Teleflex’s (TFX) segments perform in Q2 2026?

In Q2 2026, Vascular revenue was $246.3 million with 9.0% reported growth and 8.0% pro forma adjusted constant currency growth. Interventional revenue was $211.9 million (86.1% reported growth, but –1.0% pro forma adjusted constant currency), and Surgical revenue reached $112.1 million with 9.2% pro forma adjusted constant currency growth.

0000096943false00000969432026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) August 6, 2026

TELEFLEX INCORPORATED

(Exact name of Registrant as Specified in Its Charter)

Delaware			1-5353			23-1147939
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)

550 E. Swedesford Rd., Suite 400

Wayne,

PA

19087

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code

(610)

225-6800

Not applicable

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $1 per share

TFX

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 6, 2026, Teleflex Incorporated (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report.

In addition to the financial information included in the Press Release that has been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), the Press Release includes certain non-GAAP financial measures. These measures include pro forma adjusted revenue, pro forma adjusted constant currency revenue growth and adjusted diluted earnings per share. Pro forma adjusted revenue is based upon net revenues, adjusted to (i) exclude, depending on the period presented, the impact of products discontinued in the year ended December 31, 2025 due to a strategic realignment; (ii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025 and (iii) for certain periods, exclude the impact of changes in reserves for prior years related to Italian legislation requiring suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. Pro forma adjusted constant currency revenue growth is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. Adjusted diluted earnings per share is based upon diluted earnings per share available to common stockholders, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact (net of tax) of (i) restructuring and optimization charges; (ii) impairment charges, (iii) acquisition, integration and divestiture related items; (iv) separation costs related to the Company's entry into agreements to divest its Acute Care, Interventional Urology and OEM businesses (the "Strategic Divestitures"), including activities to prepare the businesses for divestiture and maintain continuity through the separation process; (v) other items identified in the reconciliation tables set forth in the Press Release, as applicable; (vi) certain expenditures associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; (viii) costs incurred in connection with our implementation of a new global enterprise resource planning system and related information technology transition costs; and (ix) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Management uses these non-GAAP financial measures to assess the Company's financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibit 99.1 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

Item 7.01. Regulation FD Disclosure.

In connection with the conference call to be held by the Company on August 6, 2026 to discuss its financial results for the quarter ended June 30, 2026, the Company plans to reference a slide presentation, which will be made available in advance of the call through the Company’s website. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.2, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise

subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

        99.1    Press Release, dated August 6, 2026

        99.2    Earnings Conference Call Slide Presentation

        104    The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.    

Date: August 6, 2026 TELEFLEX INCORPORATED

By: /s/ John R. Deren Name: John R. Deren Title: Executive Vice President and Chief Financial Officer

Exhibit 99.1

FOR IMMEDIATE RELEASE August 6, 2026

Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook

Completes Sale of OEM Business and Will Deploy Net Proceeds to Reduce Debt and Repurchase Common Stock

Announces $250 Million Accelerated Share Repurchase Program, Repurchased $250 Million of Common Stock in the Second Quarter

Wayne, PA -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026.

Second quarter 2026 continuing operations financial summary1

•Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2

•GAAP diluted EPS from continuing operations of $0.96, compared to $1.54 in the prior year period

•Adjusted diluted EPS from continuing operations of $1.76, compared to $1.73 in the prior year period

"We delivered a strong second quarter, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to strengthen the company for the future,” said Jason Weidman, Teleflex's President and Chief Executive Officer. “The completion of the OEM divestiture marks a pivotal step in our transformation, enabling greater focus on our core businesses, a stronger balance sheet, and increased financial flexibility to further reduce debt, return capital to shareholders, and invest in the opportunities that will drive long-term growth. We also made meaningful progress advancing our innovation pipeline, including important milestones for Freesolve and the Food and Drug Administration approval for EZPLAZ, reinforcing our commitment to bringing differentiated solutions to the market.”

Mr. Weidman continued, "Integration of the acquired Biotronik Vascular Intervention business is progressing, though taking longer than expected, and we updated our revenue outlook accordingly. Importantly, the delay is attributable to elongated integration timelines and not the underlying product portfolio, which remains competitively well positioned. We remain confident in the long-term strategic and financial prospects of this business as part of Teleflex, and have a number of mitigation actions underway to address the primary drivers of the delay. Our updated outlook also reflects the benefits of our disciplined capital allocation actions, including an increase to our adjusted EPS guidance."

Turning to his priorities as CEO, Weidman said: "I’m encouraged by the progress our team is making across the organization. Looking ahead, I am focused on completing a thorough assessment of the business and sharpening our strategic and operating plan to maximize shareholder value. My priorities are operational rigor, accelerating our innovation-driven

1

platforms, and disciplined capital deployment. We believe these efforts will position Teleflex to deliver a meaningfully stronger financial profile in 2027 and beyond."

2026 continuing operations guidance summary1

•Reducing GAAP revenue growth guidance range to 13.40% to 14.40%

•Reducing GAAP EPS from continuing operations guidance range to $2.54 to $2.84

•Reducing pro forma adjusted constant currency revenue growth guidance range to 3.50% to 4.50%2

•Increasing Adjusted diluted EPS from continuing operations guidance range to $6.90 to $7.20

◦Includes an assumption of approximately 19% adjusted operating margin for 2026 inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture

◦Reflects execution of capital allocation strategy including $250 million of share repurchase activity in the second quarter of 2026 and pay off of ~$700 million Term Loan A-2

◦Excludes expected benefits from TS and manufacturing services ("MS") agreements that come into effect upon closing the Acute Care and Interventional Urology Strategic Divestiture

◦Excludes the impact of the announced $250 million Accelerated Share Repurchase and other anticipated future repurchases under previously announced $1 billion share repurchase program primarily funded with proceeds from the Strategic Divestitures

◦Adjusted diluted EPS from continuing operations excludes any impact of potential IEEPA tariff refunds

(1) Continuing operations excludes the Acute Care, Interventional Urology, and OEM businesses that were classified as discontinued operations during the fourth quarter of 2025 as a result of our entry into agreements to divest those businesses, which we refer to as the “Strategic Divestitures".

(2) Pro forma adjusted constant currency revenue growth includes revenue generated by the acquired Vascular Intervention business in the prior year period, and excludes (a) revenue generated by products previously included within continuing operations that were discontinued at the end of 2025 due to a strategic realignment, (b) the impact of the Italian payback measure, and (c) the impact of foreign exchange.

INNOVATION PIPELINE UPDATE

EZPLAZ BLA Approval

In late July, Teleflex received BLA approval from the U.S. Food and Drug Administration for EZPLAZ™ Freeze Dried Plasma, the first freeze-dried plasma licensed by the FDA. EZPLAZ expands the emergency medicine portfolio within the Company’s Vascular business and is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage) when plasma is required and other plasma products are unavailable, including in combat and prehospital settings.

Freesolve Clinical Program Advances

Within Interventional, Teleflex continued to advance its clinical program for Freesolve™, a novel drug-eluting resorbable magnesium scaffold. During the quarter, the Company presented four-year follow-up data from the BIOMAG-I study demonstrating sustained long-term performance and a favorable long-term safety profile; completed enrollment, ahead of schedule, in the BIOMAG-II study, the first randomized controlled trial of Freesolve conducted outside the United States, positioning the Company for a data readout in late 2027; and initiated the U.S. BIOMAG-III pivotal trial, with first patient procedures completed in June at MedStar Washington Hospital Center.

2

CAPITAL ALLOCATION AND BALANCE SHEET ACTIVITY

OEM Divestiture and Debt Reduction

As previously disclosed, the Company completed the divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The Company estimates after-tax proceeds of approximately $1.25 billion. The Company paid off its $700 million Term Loan A-2 associated with our acquisition of substantially all of Biotronik's Vascular Intervention business.

Share Repurchase

As previously disclosed, on December 9, 2025, the Board of Directors authorized a share repurchase program for up to $1 billion of the Company's common stock. During the second quarter, as part of the share repurchase program, the Company repurchased 1.9 million shares of common stock for $250 million through open market transactions at an average price per share of $130.85. As of June 30, 2026, the Company had $750 million remaining available under the authorization.

Also under the $1 billion share repurchase program, the Company intends to commence an accelerated share repurchase of $250 million of common stock, effective August 7, 2026.

Senior Credit Facility and Notes

During the second quarter, the Company entered into a new credit agreement, which effectuated the refinancing of the Company’s prior credit agreement. The new credit agreement provides for, among other things, a $1 billion revolving credit facility and a $500 million term A-1 loan facility, both of which mature on May 26, 2031, and a $700 million term A-2 loan facility, which matures on May 26, 2028.

Also during the second quarter, the Company completed a private offering of $500 million aggregate principal amount of 5.875% senior notes due 2032. The Company used the net proceeds, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027.

NET REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding net revenues in each of the Company's global product categories for the three and six months ended June 30, 2026 and the comparable prior year period on both a GAAP and pro forma adjusted constant currency basis.

			Three Months Ended																																										% Increase			/			(Decrease)
			June 30, 2026																		June 29, 2025
			Reported revenue						Adjustment						Pro Forma Adjusted Revenue						Reported revenue						Adjustment						Pro Forma Adjusted Revenue						Reported Revenue Growth						Currency Impact						Adjustment impact						Pro Forma Adjusted Constant Currency Revenue Growth
Vascular			$246.3						$—						$246.3						$225.9						$—						$225.9						9.0%						1.0%						—%						8.0%
Interventional1			211.9						—						211.9						113.8						100.4						214.2						86.1%						(0.2)%						87.3%						(1.0)%
Surgical2			112.1						—						112.1						102.8						(0.5)						102.3						9.1%						0.3%						(0.4)%						9.2%
Consolidated1			$570.3						$—						$570.3						$442.5						$99.9						$542.4						28.9%						0.4%						23.8%						4.7%

3

			Six Months Ended																																										% Increase			/			(Decrease)
			June 30, 2026																		June 29, 2025
			Reported revenue						Adjustment						Pro Forma Adjusted Revenue						Reported revenue						Adjustment						Pro Forma Adjusted Revenue						Reported Revenue Growth						Currency Impact						Adjustment impact						Pro Forma Adjusted Constant Currency Revenue Growth
Vascular			$483.2						$—						$483.2						$445.0						$—						$445.0						8.6%						2.2%						—%						6.4%
Interventional1			416.5						—						416.5						214.0						193.0						407.0						94.6%						1.4%						92.3%						0.9%
Surgical2			218.9						—						218.9						197.8						(1.0)						196.8						10.7%						1.7%						(0.6)%						9.6%
Consolidated1			$1,118.6						$—						$1,118.6						$856.8						$192.0						$1,048.8						30.6%						1.8%						23.9%						4.9%

Notes: (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments.

(2) Adjustments are inclusive of discontinued product adjustments

See Pro Forma Adjusted Revenue by Global Product Category table for reconciliation of adjustments.

4

OTHER CONTINUING OPERATIONS FINANCIAL HIGHLIGHTS

•Depreciation expense, amortization of intangible assets and deferred financing charges for the six months ended June 30, 2026 totaled $106.5 million compared to $77.2 million for the prior year period.

•Total cash, cash equivalents and restricted cash equivalents at June 30, 2026 were $316.9 million compared to $402.7 million at December 31, 2025.

•Net accounts receivable at June 30, 2026 were $364.6 million compared to $345.6 million at December 31, 2025.

•Inventories at June 30, 2026 were $351.9 million compared to $404.4 million at December 31, 2025.

2026 CONTINUING OPERATIONS OUTLOOK

On a GAAP basis, the Company reduced its full year 2026 revenue growth from continuing operations outlook to 13.40% to 14.40%, including our estimate of an approximately 0.70% positive impact of foreign exchange rate fluctuations. On a pro forma adjusted constant currency basis, the Company reduced its full year 2026 revenue growth from continuing operations outlook to 3.50% to 4.50%.

The Company reduced its full year 2026 GAAP diluted earnings per share from continuing operations outlook range of $2.54 to $2.84. The Company increased its full year 2026 adjusted diluted earnings per share from continuing operations outlook to $6.90 to $7.20.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation

			2025						2026 Guidance
									Low						High
GAAP revenue			$1,992.7						$2,260						$2,280
Vascular Intervention pro forma adjustment			$199.0						—						—
Discontinued product adjustment			$(14.3)						—						—
Italian payback measure adjustment			$(9.0)						—						—
Pro forma adjusted revenue			$2,168.4						$2,260						$2,280

Forecasted 2026 Pro Forma Adjusted Constant Currency Revenue Percent Growth From Continuing Operations Reconciliation

			Low						High
Forecasted 2026 GAAP revenue growth			13.4%						14.4%
Vascular Intervention pro forma adjustment			10.0%						10.0%
Discontinued product adjustment			(0.7)%						(0.7)%
Italian payback measure adjustment			(0.5)%						(0.5)%
Base year adjustment (GAAP versus pro forma adjusted)			0.4%						0.4%
Estimated impact of foreign currency exchange rate fluctuations			0.7%						0.7%
Forecasted 2026 pro forma adjusted constant currency revenue growth			3.5%						4.5%

5

Forecasted 2026 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

			Low						High
Forecasted GAAP diluted earnings per share from continuing operations			$2.54						$2.84
Restructuring and optimization items, net of tax			$0.98						$0.98
Acquisition, integration and divestiture related items, net of tax			$0.73						$0.73
Other items, net of tax			$(0.42)						$(0.42)
ERP implementation, net of tax			$0.31						$0.31
MDR, net of tax			$0.02						$0.02
Intangible amortization expense, net of tax			$2.74						$2.74
Forecasted adjusted diluted earnings per share from continuing operations, net of tax			$6.90						$7.20

6

CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION

A webcast of Teleflex's second quarter 2026 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on August 6, 2026.

An audio replay of the investor call will be available beginning at 11:00 am ET on August 6, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909(all other locations). The confirmation code is 69028.

ADDITIONAL NOTES

References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future.

Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

NOTES ON NON-GAAP FINANCIAL MEASURES

We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: pro forma adjusted revenues, pro form adjusted constant currency revenue growth, and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

7

Pro forma adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; (ii) exclude the items described in Italian payback measure; and (iii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025.

Pro forma adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges.

Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or

8

assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed.

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance.

Other - These are discrete items that occur sporadically and can affect period-to-period comparisons.

European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

9

ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

PRO FORMA ADJUSTED REVENUE BY GLOBAL PRODUCT CATEGORY

The following table provides information regarding pro forma adjusted revenues in each of the Company's global product categories in continuing operations for the three and six months ended June 30, 2026 and the comparable prior year period.

			Three Months Ended									Six Months Ended
			June 30, 2026			June 29, 2025						June 30, 2026			June 29, 2025
Vascular			246.3			225.9						483.2			445.0
Interventional			211.9			113.8						416.5			214.0
Surgical			112.1			102.8						218.9			197.8
GAAP revenue			570.3			442.5						1,118.6			856.8
Interventional - Vascular Intervention			—			103.8						—			199.0
Interventional - Discontinued Products			—			(3.4)						—			(6.0)
Surgical - Discontinued Products			—			(0.5)						—			(1.0)
Pro forma adjusted revenue			$570.3			$542.4						$1,118.6			$1,048.8
Vascular			246.3			225.9						483.2			445.0
Interventional			211.9			214.2						416.5			407.0
Surgical			112.1			102.3						218.9			196.8

10

Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Three Months Ended June 30, 2026
			Revenue			Gross margin			SG&A (1)			R&D (1)			Operating margin (2)			Income before income taxes			Income tax expense			Effective income tax rate			Diluted earnings per share from continuing operations
GAAP Basis - Continuing Operations			$570.3			58.2%			37.4%			7.9%			12.8%			$45.1			$3.4			7.5%			$0.96
Adjustments
Restructuring and optimization charges (A)			—			0.3			(1.6)			—			1.9			10.9			1.9						0.20
Acquisition, integration and divestiture related items (B)			—			—			(1.7)			—			1.7			9.9			1.8						0.18
Other items (C)			—			—			3.6			—			(3.6)			(19.3)			(4.0)						(0.35)
ERP implementation			—			—			(0.7)			—			0.7			4.0			0.7						0.08
MDR			—			—			—			(0.1)			0.1			0.3			—						0.01
Intangible amortization expense			—			3.2			(2.8)			—			6.0			34.1			4.6						0.68
Adjustments total			—			3.5			(3.2)			(0.1)			6.8			39.9			5.0						0.80
Adjusted basis			$570.3			61.7%			34.2%			7.8%			19.6%			$85.0			$8.4			9.9%			$1.76

Three Months Ended June 29, 2025
			Revenue			Gross margin			SG&A (1)			R&D (1)			Operating margin (2)			Income before income taxes			Income tax expense			Effective income tax rate			Diluted earnings per share from continuing operations
GAAP Basis - Continuing Operations			$442.5			60.1%			31.1%			6.0%			20.6%			$70.7			$2.5			3.5%			$1.54
Adjustments
Restructuring and optimization charges (A)			—			1.4			—			—			1.7			7.4			1.2						0.14
Impairment charges			—			—			—			—			1.8			8.1			1.8						0.14
Acquisition, integration and divestiture related items (B)			—			—			6.4			—			(6.4)			(27.9)			2.1						(0.68)
Separation costs			—			—			—			—			0.3			1.3			—						0.03
Other items (C)						—			—			—			—			0.1			—						—
ERP implementation			—			—			(0.9)			—			0.9			3.8			0.5						0.07
MDR			—			—			—			(0.2)			0.2			0.9			—						0.02
Intangible amortization expense			—			3.0			(2.7)			—			5.7			25.1			3.0						0.50
Tax adjustments			—			—			—			—			—			—			1.4						(0.03)
Adjustments total			—			4.4			2.8			(0.2)			4.2			18.8			10.0						0.19
Adjusted basis			$442.5			64.5%			33.9%			5.8%			24.8%			$89.5			$12.5			14.1%			$1.73

11

Six Months Ended June 30, 2026
			Revenue			Gross margin			SG&A (1)			R&D (1)			Operating margin (2)			Income before income taxes			Income tax expense			Effective income tax rate			Diluted earnings per share from continuing operations
GAAP Basis - Continuing Operations			$1,118.6			57.1%			39.3%			8.0%			8.3%			$41.3			$4.4			10.6%			$0.84
Adjustments
Restructuring and optimization charges (A)			—			0.5			(1.5)			—			3.5			39.0			6.3						0.73
Acquisition, integration and divestiture related items (B)			—			0.7			(1.3)			—			1.9			22.9			5.0						0.41
Other items (C)			—			—			1.8			—			(1.8)			(19.2)			(4.0)						(0.35)
ERP implementation			—			—			(0.7)			—			0.7			7.9			1.3						0.15
MDR			—			—			—			(0.1)			0.1			0.7			—						0.02
Intangible amortization expense			—			3.2			(2.9)			—			6.1			67.9			9.2						1.34
Adjustments total			—			4.4			(4.6)			(0.1)			10.5			119.2			17.8						2.30
Adjusted basis			$1,118.6			61.5%			34.7%			7.9%			18.8%			$160.5			$22.2			13.8%			$3.14

Six Months Ended June 29, 2025
			Revenue			Gross margin			SG&A (1)			R&D (1)			Operating margin (2)			Income before income taxes			Income tax expense			Effective income tax rate			Diluted earnings per share from continuing operations
GAAP Basis - Continuing Operations			$856.8			60.8%			33.9%			6.0%			19.5%			$129.4			$8.9			6.9%			$2.67
Adjustments
Restructuring and optimization charges (A)			—			1.3			—			—			1.6			13.5			2.3						0.25
Impairment charges			—			—			—			—			0.9			8.1			1.8						0.14
Acquisition, integration and divestiture related items (B)			—			—			5.4			—			(5.4)			(46.0)			2.9						(1.07)
Separation costs			—			—			—			—			0.2			1.3			—						0.03
Other items (C)			—			—			—			—			—			0.1			—						—
ERP implementation			—			—			(1.1)			—			1.1			9.7			1.5						0.18
MDR			—			—			—			(0.2)			0.2			1.6			—						0.03
Intangible amortization expense			—			3.1			(2.8)			—			5.9			50.7			6.1						0.99
Tax adjustments			—			—			—			—			—			—			2.1						(0.05)
Adjustments total			—			4.4			1.5			(0.2)			4.5			39.0			16.7						0.50
Adjusted basis			$856.8			65.2%			35.4%			5.8%			24.0%			$168.4			$25.6			15.2%			$3.17

Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.

(2) Operating margin defined as Income from continuing operations before interest and taxes as a percentage of as reported and adjusted revenues.

Totals may not sum due to rounding.

12

Tickmarks to Reconciliation Tables

(A)Restructuring and optimization charges – For the three months ended June 30, 2026, pre-tax restructuring charges were $0.2 million and restructuring related charges were $10.6 million. For the three months ended June 29, 2025, pre-tax restructuring charges were $1.3 million, restructuring related charges were $3.5 million, and product optimization charges were $2.6 million. For the six months ended June 30, 2026, pre-tax restructuring charges were $17.1 million and restructuring related charges were $21.9 million, partially offset by a benefit from product rationalization charges of $0.1 million. For the six months ended June 29, 2025, pre-tax restructuring charges were $2.7 million, restructuring related charges were $8.2 million, and product optimization charges were $2.6 million.

(B)Acquisition, integration and divestiture related items – For the three and six months ended June 30, 2026, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended June 30, 2026 these charges included acquisition and integration costs of $8.9 million. For the six months ended June 30, 2026 these charges included acquisition and integration costs of $16.7 million and inventory step up costs of $8.0 million. For the three and six months ended June 29, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the three months ended June 29, 2025 the charges included acquisition and integration costs of $15.8 million, which were offset by a benefit of $59.7 million related to non-designated foreign currency forward contracts. For the six months ended June 29, 2025 the charges included acquisition and integration costs of $22.1 million, which were offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts.

(C)Other – For the three and six months ended June 30, 2026, other items included a benefit from a litigation settlement of $25.0 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $3.6 million, a loss on extinguishment of debt of $1.2 million, and charges incurred in connection with the credit agreement refinancing of $1.0 million. For the three and six months ended June 29, 2025, other items included expenses associated with prior year tax matters.

13

ABOUT TELEFLEX INCORPORATED

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

CAUTION CONCERNING FORWARD-LOOKING INFORMATION

This press release contains forward-looking statements, including, but not limited to, the implementation and execution of our share repurchase program, including our planned accelerated share repurchase; our intended use of proceeds from the OEM divestiture; our expectations with respect to our financial profile in 2027 and beyond; forecasted 2026 GAAP, pro forma adjusted and pro forma adjusted constant currency revenue and revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2026 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, unanticipated difficulties and expenditures in connection with integration programs; the possibility that the Strategic Divestitures do not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the Strategic Divestitures; customer and shareholder reaction to the Strategic Divestitures; disruption from the Strategic Divestitures that may make it more difficult to maintain business and operational relationships; significant transaction costs; delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; risks relating to the activities of activist stockholders; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, tariffs, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.

14

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

			Three Months Ended												Six Months Ended
			June 30, 2026						June 29, 2025						June 30, 2026						June 29, 2025
			(Dollars and shares in thousands, except per share)
Net revenues			$	570,332					$	442,525					$	1,118,594					$	856,783
Cost of goods sold			238,625						176,695						479,461						335,522
Gross profit			331,707						265,830						639,133						521,261
Selling, general and administrative expenses			213,515						137,504						439,527						290,419
Research and development expenses			45,122						26,488						89,508						51,783
Restructuring charges, separation costs and impairment charges			246						10,700						17,091						12,122
Income from continuing operations before interest, taxes and loss on extinguishment of debt			72,824						91,138						93,007						166,937
Interest expense			27,953						21,703						53,671						40,240
Interest income			(1,416)						(1,229)						(3,124)						(2,717)
Loss on extinguishment of debt			1,150						—						1,150						—
Income from continuing operations before taxes			45,137						70,664						41,310						129,414
Taxes on income from continuing operations			3,375						2,489						4,386						8,906
Income from continuing operations			41,762						68,175						36,924						120,508
Operating income from discontinued operations			60,254						64,577						57,611						114,637
Taxes on operating income from discontinued operations			2,323						10,172						2,996						17,563
Income from discontinued operations			57,931						54,405						54,615						97,074
Net income			$	99,693					$	122,580					$	91,539					$	217,582
Earnings per share:
Basic:
Income from continuing operations			$	0.96					$	1.54					$	0.84					$	2.68
Income from discontinued operations			1.33						1.23						1.24						2.15
Net income			$	2.29					$	2.77					$	2.08					$	4.83
Diluted:
Income from continuing operations			$	0.96					$	1.54					$	0.84					$	2.67
Income from discontinued operations			1.32						1.23						1.24						2.15
Net income			$	2.28					$	2.77					$	2.08					$	4.82
Weighted average common shares outstanding
Basic			43,562						44,269						43,908						45,017
Diluted			43,660						44,332						44,014						45,120

15

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

			June 30, 2026						December 31, 2025
			(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents			$	300,159					$	378,564
Accounts receivable, net			364,609						345,583
Inventories			351,912						404,395
Prepaid expenses and other current assets			148,222						150,678
Prepaid taxes			36,458						19,566
Current assets of discontinued operations			674,516						639,552
Total current assets			1,875,876						1,938,338
Property, plant and equipment, net			475,637						498,281
Operating lease assets			77,158						91,817
Goodwill			2,292,435						2,305,050
Intangible assets, net			1,448,669						1,524,150
Deferred tax assets			12,642						12,593
Other assets			120,310						112,984
Non-current assets of discontinued operations			484,051						464,026
Total assets			6,786,778						6,947,239
LIABILITIES AND EQUITY
Current liabilities
Current borrowings			$	87,500					$	100,000
Accounts payable			143,292						130,201
Accrued expenses			134,170						117,350
Payroll and benefit-related liabilities			110,214						124,769
Accrued interest			3,558						5,404
Income taxes payable			17,787						18,787
Other current liabilities			88,364						137,195
Current liabilities of discontinued operations			135,494						128,320
Total current liabilities			720,379						762,026
Long-term borrowings			2,720,509						2,541,449
Deferred tax liabilities			146,141						183,749
Noncurrent liability for uncertain tax positions			3,802						3,536
Noncurrent operating lease liabilities			64,540						84,210
Other liabilities			174,899						194,532
Non-current liabilities of discontinued operations			51,974						52,969
Total liabilities			3,882,244						3,822,471
Commitments and contingencies
Total shareholders' equity			2,904,534						3,124,768
Total liabilities and shareholders' equity			$	6,786,778					$	6,947,239

16

TELEFLEX INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

			Six Months Ended
			June 30, 2026						June 29, 2025
			(Dollars in thousands)
Cash flows from operating activities of continuing operations:
Net income			$	91,539					$	217,582
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations			(54,615)						(97,074)
Depreciation expense			35,620						24,840
Intangible asset amortization expense			67,943						50,668
Deferred financing costs and debt discount amortization expense			2,976						1,705
Loss on extinguishment of debt			1,150						—
Changes in contingent consideration			(2,699)						14,080
Stock-based compensation			12,182						12,287
Asset impairment charge			—						8,117
Gain on non-designated foreign currency forward contracts			—						(83,532)
Deferred income taxes, net			(16,090)						(1,935)
Interest benefit on swaps designated as net investment hedges			(15,422)						(7,484)
Other			3,140						(6,388)
Changes in assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable			(23,639)						(26,559)
Inventories			44,252						(13,949)
Prepaid expenses and other assets			12,888						(3,734)
Accounts payable, accrued expenses and other liabilities			(6,053)						(27,643)
Income taxes receivable and payable, net			(14,613)						(70,277)
Net cash provided by (used in) operating activities from continuing operations			138,559						(9,296)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment			(32,825)						(51,921)
Payments for businesses and intangibles acquired, net of cash acquired			—						(6,700)
Insurance settlement proceeds			—						9,447
Net payments on swaps designated as net investment hedges			(39,542)						7,612
Purchase of investments			(9,000)						(5,000)
Net cash used in investing activities from continuing operations			(81,367)						(46,562)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings			2,350,000						300,000
Reduction in borrowings			(2,175,000)						(55,375)
Repurchase of common stock			(250,000)						(300,000)
Net (payments) proceeds from share based compensation plans and related tax impacts			(5,265)						7,207
Share repurchase excise tax			(2,802)						(1,894)
Payments for contingent consideration			(107)						(112)
Dividends paid			(29,830)						(30,218)
Debt issuance and amendment fees			(13,981)						(2,800)
Net cash used in financing activities from continuing operations			(126,985)						(83,192)
Cash flows from discontinued operations:
Net cash provided by operating activities			4,796						90,131
Net cash used in investing activities			(18,144)						(12,718)
Net cash (used in) provided by discontinued operations			(13,348)						77,413
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents			(6,420)						17,908
Net decrease in cash, cash equivalents and restricted cash equivalents			(89,561)						(43,729)
Cash, cash equivalents and restricted cash equivalents at the beginning of the period			453,848						327,650
Less: Cash, cash equivalents and restricted cash of discontinued operations			(47,368)						(27,365)
Cash, cash equivalents and restricted cash equivalents at the end of the period			$	316,919					$	256,556

17

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

investors.teleflex.com

610-948-2836

18

Second Quarter 2026 Earnings Conference Call 8/6/2026 Teleflex Incorporated Exhibit 99.2

The release, accompanying slides, and replay webcast are available online at www.teleflex.com (click on Investors) An audio replay of the call will be available beginning at 11:00 am Eastern Time on August 6, 2026 either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S.) or 1 609 800 9909 (all other locations). The confirmation code is 69028. Conference Call Logistics

Today’s Speakers TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026 Lawrence Keusch VP, Investor Relations and Strategy Development Jason Weidman President and CEO John Deren Executive VP and CFO

TELEFLEX EARNINGS CONFERENCE CALL 8/6/20264 Additional Notes This document contains certain highlights with respect to our second quarter 2026 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended June 30, 2026 located in the investor section of our website at www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 to be filed with the Securities and Exchange Commission. Unless otherwise noted, the following slides reflect continuing operations. This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements regarding our planned uses of the net proceeds from the closing of the sale of our OEM business (the “OEM Strategic Divestiture”), including, without limitation, with respect to the paydown of debt and the repurchase of shares our outstanding common stock; our plans to commence an accelerated share repurchase; statements regarding our expectations with respect to the timing for closing of the sales of our Acute Care and Interventional Urology businesses (which, together with the OEM Strategic Divestiture, we refer to as the “Strategic Divestitures”); statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that the transition services and manufacturing services agreements to be entered into in connection with the Strategic Divestitures will offset stranded costs on an annualized basis; our expectation that our financial portfolio will be meaningfully stronger starting in 2027; statements regarding our BIOMAG-II and BIOMAG-III pivotal trials; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward–looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented. Note on Forward-Looking Statements Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins, adjusted selling, general and administrative expenses, adjusted research and development expenses, adjusted income before taxes, adjusted income tax expense and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

Jason Weidman President and CEO Executive Overview

Q2 Performance Summary ◦ Closed the OEM Strategic Divestiture for approximately $1.5 billion in proceeds ($1.25 billion after-tax) ◦ OEM Strategic Divestitures generates the majority of our expected proceeds from the Strategic Divestitures — funds debt paydown and share repurchase ◦ Q2'26 pro forma adjusted constant currency revenue grew 4.7% year-over-year ◦ Q2'26 adjusted gross margin of 61.7% and adjusted operating margin of 19.6% ◦ Q2'26 adjusted EPS of $1.76, a 1.7% increase year-over-year Q2'26 Highlights OEM Divestiture Update Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. TELEFLEX EARNINGS CONFERENCE CALL 8/6/2026

Rx Only See appendices to this presentation for EZPLAZ™ Freeze Dried Plasma Indications and Important Safety Information. EZPLAZTM Freeze Dried Plasma Receives FDA BLA Approval – First freeze dried plasma licensed by the FDA; expands the emergency medicine portfolio within our Vascular and Emergency Medicine business – Approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma coagulation factors, including uncontrolled bleeding (hemorrhage), when plasma is required and other plasma products are not available – Enables plasma transfusion in situations where it is critically needed – on the battlefield, in the hospital, and on air and road ambulances – Patented flexible plastic bag technology enables quick and efficient reconstitution of freeze dried plasma – Overcomes the logistical and operational limits of traditional plasma products – freezers, thawing equipment, long thaw times, and post-thaw refrigeration1,2 Innovation Updates TELEFLEX EARNINGS CONFERENCE CALL 8/6/20267 FDA BLA APPROVAL EZPLAZTM Freeze Dried Plasma First freeze dried plasma licensed by the FDA – overcoming logistical and operational limitations of traditional plasma products1,2 1.Pusateri AE, Given MB, Schreiber MA, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56 Suppl 2:S128-S139. doi:10.1111/ trf.13580 2.Hervig T, Doughty H, Ness P, et al. Prehospital use of plasma: the blood bankers' perspective. Shock. 2014;41 Suppl 1:39-43. doi:10.1097/SHK.0000000000000144

CAUTION—Investigational device. Limited by the United States law to investigational use. FreesolveTM RMS is not for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location. BIOMAG-I: Four-Year Data Confirms Durable FreesolveTM Resorbable Magnesium Scaffold (RMS) Performance – Announced four-year follow-up data from the single-arm BIOMAG-I study, confirming the long-term, sustained performance of FreesolveTM RMS 1 – Favorable long-term safety profile, with no new cardiac-related events observed between the two and four- year follow-up1 Advancing the Clinical Program: BIOMAG-II and BIOMAG-III – BIOMAG-II: initial European & Asia Pacific randomized controlled trial – BIOMAG-III: U.S. pivotal trial Innovation Updates TELEFLEX EARNINGS CONFERENCE CALL 8/6/20268 Differentiated Freesolve combines temporary scaffolding with drug delivery to target rapidly growing interventional trend to “leave nothing behind” Late-2027 BIOMAG-II: first randomized clinical data readout expected *Target Lesion Failure is a composite of Cardiac Death, Target Vessel Q-wave or non-Q wave Myocardial Infarction, or clinically driven Target Lesion Revascularization (TLR). 1.Torzewski, J. Lessons from the long-term DES data: how they can inform today's practice - BIOMAG-I: 4-Year Clinical Outcomes of the Resorbable Magnesium Scaffold- DREAMS 3G. pcronline.com Published May 20, 2026. Accessed June 3, 2026. https://www.pcronline.com/Cases-resources-images/Resources/Course-videos-slides/2026/ EuroPCR/Lessons-from-the-long-term-DES-data-how-they-can-inform-today-s-practice?auth=true. Research sponsored by Teleflex. – Completed patient enrollment ahead of schedule – One-year follow-up data vs. XIENCETM Drug-Eluting Stent (DES) expected in late 2027 – Study will enroll 1,859 patients at up to 120 sites worldwide, comparing FreesolveTM RMS to the XIENCETM Drug-Eluting Stent (DES) on 12-month target lesion failure rate* – First patient procedure completed in June at MedStar Health

Q2'26 Global Product Commentary of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 8/6/20269 Vascular Interventional Sales ($M) Commentary • In Q2'26 growth was primarily driven by growth in hemostatic products and the central access portfolio Surgical • The performance for Q2'26 was led by growth in hemostatic products, right heart catheters, intraosseous, and complex catheters offset by continued integration and restructuring activities $246.3 Reported rev. growth: 9.0% Pro forma adj. const. curr. rev. growth: 8.0% Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period. $211.9 Reported rev. growth: 86.1% Pro forma adj. const. curr. rev. growth: (1.0)% $112.1 Reported rev. growth: 9.1% Pro forma adj. const. curr. rev. growth: 9.2% • Q2'26 growth was primarily driven by strong performances in ligation clips, the instrument portfolio, and skin stapling

Three Months Ended June 30, 2026 June 30, 2026 June 29, 2025 % Increase / (Decrease) Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Vascular $246.3 $— $246.3 $225.9 $— $225.9 9.0% 1.0% —% 8.0% Interventional1 211.9 — 211.9 113.8 100.4 214.2 86.1% (0.2)% 87.3% (1.0)% Surgical2 112.1 — 112.1 102.8 (0.5) 102.3 9.1% 0.3% (0.4)% 9.2% Consolidated1 $570.3 $— $570.3 $442.5 $99.9 $542.4 28.9% 0.4% 23.8% 4.7% TELEFLEX EARNINGS CONFERENCE CALL 8/6/202610 Q2'26 Global Product Category Revenue Review Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments (2) Adjustments are inclusive of discontinued product adjustments

John Deren Executive VP and CFO Financial Overview

$1.73 $1.76 2025 2026 Q2'26 Financial Review of Continuing Operations TELEFLEX EARNINGS CONFERENCE CALL 8/6/202612 Note: See appendices for reconciliations of non-GAAP financial information. 64.5% 61.7% 2025 2026 SG&A Expense (% of Sales) Gross Margin R&D Expense (% of Sales) Operating Margin Earnings per Share ◦ the adverse impact of tariffs ◦ the addition of the Vascular Intervention business, which has a slightly lower gross margin than the corporate average ◦ year-over-year gross margin pressure ◦ higher operating expenses associated with the acquired Vascular Intervention business as well as increased R&D investment ◦ a lower share count and tax rate and, to a lesser extent, higher adjusted operating income ◦ partially offset by tariffs and higher interest expense ◦ The year-over-year adjusted operating margin decline was driven by the following: ◦ The year-over-year adjusted gross margin decline was primarily driven by the following: ◦ The year-over-year adjusted earnings per share increase was driven by the following: 24.8% 19.6% 2025 2026 ◦ operating expenses associated with the acquired Vascular Intervention business ◦ The year-over-year adjusted SG&A expense % of sales increase was driven by the following: ◦ higher R&D expenses associated primarily with the Vascular Intervention acquisition ◦ The year-over-year adjusted R&D expense % of sales increase was driven by the following: (280) bps (520) bps 33.9% 34.2% 2025 2026 5.8% 7.8% 2025 2026 Adjusted GAAP $1.54 $0.96 2025 2026 60.1% 58.2% 2025 2026 20.6% 12.8% 2025 2026 31.1% 37.4% 2025 2026 6.0% 7.9% 2025 2026

Capital return commitment • $1 billion share repurchase authorization and $800 million reduction in debt • Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures Q2 share repurchases • Repurchased approximately 1.9 million shares for $250 million through open market transactions • Average price of $130.85 per share, under the previously announced $1 billion repurchase authorization OEM divestiture proceeds deployment • With the close of the OEM divestiture, which resulted in proceeds of approximately $1.5 billion and estimated after-tax proceeds of $1.25 billion, intend to commence a $250 million accelerated share repurchase (ASR) on August 7 • Remaining net proceeds from OEM divestiture to be used primarily to: ◦ Pay down the $700 million Term Loan A-2 associated with the Vascular Intervention acquisition ◦ Replenish funds deployed for the $250 million share repurchase completed during the second quarter 13 Capital Allocation Strategy Update

14 Revenue ◦ Reducing 2026 pro forma adjusted constant currency revenue growth range to 3.50% to 4.5% year-over-year ◦ Reducing 2026 GAAP revenue from continuing operations growth range to 13.40% to 14.4% year-over-year Earnings Per Share ◦ Increasing 2026 Adjusted diluted EPS from continuing operations range to $6.90 to $7.20 ◦ Reducing 2026 GAAP EPS from continuing operations range to $2.54 to $2.84 2026 Financial Guidance Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

2026 Guidance Considerations 15 Pro Forma Adj. CC Revenue Growth ◦ 3.50% to 4.5% pro forma adjusted constant currency revenue growth for 2026 Adjusted Earnings Per Share ◦ 2026 adjusted EPS from continuing operations in the range of $6.90 to $7.20 ◦ Excludes foreign exchange, Italian payback matter, and discontinued products ◦ Includes Vascular Intervention revenue for the first half of 2025 ◦ ~19.0% adjusted operating margin inclusive of transition services ("TS") associated with the close of the OEM Strategic Divestiture ◦ ~12.25% tax rate ◦ $85M of interest expense ◦ Reflects capital allocation execution: $250M share repurchases in Q2 2026 and payoff of ~$700M Term Loan A-2 ◦ Excludes TS and manufacturing services ("MS") benefits from the Acute Care & Interventional Urology Divestiture ◦ Excludes the $250M ASR and future repurchases under the $1B buyback program funded by Strategic Divestitures proceeds ◦ Excludes potential IEEPA tariff refund impact ◦ Excludes incremental debt paydown with net proceeds from the Strategic Divestitures ◦ Assumes: Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

16 Adjusted Operating Margin Debt Paydown ◦ Intend to pay down ~$800 million in debt, including debt associated with the Vascular Intervention acquisition, with net proceeds from the Strategic Divestitures Share Repurchase ◦ Remaining $750 million authorization under previously announced share repurchase program to be funded with net proceeds from the Strategic Divestitures 2026 Financial Guidance – Future Opportunities ◦ TS/MS agreements expected to offset stranded costs on an annualized basis ◦ Previously announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis upon completion in mid-2028, which will contribute to mitigating stranded costs

2026 Financial Guidance of Continuing Operations Summary TELEFLEX EARNINGS CONFERENCE CALL 8/6/202617 2026 Guidance Low High GAAP Revenue Growth 13.4% 14.4% Impact of Vascular Intervention Pro Forma 10.0% 10.0% Impact of Discontinued Product (0.7)% (0.7)% Impact of Italian Payback Measure (0.5)% (0.5)% Base Year Adjustment (GAAP Versus Pro Forma Adjusted) 0.4% 0.4% Impact of Foreign Exchange Rate Fluctuations 0.7% 0.7% Pro Forma Adjusted Constant Currency Revenue Growth 3.5% 4.5% Adjusted Operating Margin ~19% Adjusted EPS $6.90 $7.20 Adjusted EPS % Growth (1.1)% 3.2% Note: See appendices for reconciliations of non-GAAP financial information.

Forecasted 2026 Pro Forma Adjusted Revenue From Continuing Operations Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 8/6/202618 2026 Guidance 2025 2026 Guidance Low High GAAP revenue $1,992.7 $2,260 $2,280 Vascular Intervention pro forma adjustment 199.0 — — Discontinued product adjustment (14.3) — — Italian payback measure adjustment (9.0) — — Pro forma adjusted revenue $2,168.4 $2,260 $2,280 Note: See appendices for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 8/6/202619 Key Takeaways Solid Q2 Performance but with Interventional Integration Challenges • Vascular & Surgical delivered excellent H1 results • Interventional integration slower than planned; mitigations underway • Reduced adjusted revenue guidance to reflect dynamics Committed to Significant Capital Return to Shareholders • Executing to total of $1B share repurchase & $800M debt reduction • Accelerated capital reallocation in H1 driving increase in adjusted EPS guidance • Completed OEM divestiture will fuel additional repurchases & debt reduction Portfolio Transformation Positions for Acceleration in 2027+ • Successfully executing towards more streamlined portfolio • Meaningfully stronger financial profile starting in 2027 • Positive innovation milestones highlight increased focus on future growth opportunities

TELEFLEX EARNINGS CONFERENCE CALL 8/6/202620 Thank You!

Appendices

The presentation to which these appendices are attached and the following appendices include, among other things, tables reconciling the following applicable non-GAAP financial measures to the most comparable GAAP financial measure: Pro forma adjusted revenue. This non-GAAP measure is based upon net revenues, adjusted to (i) exclude products discontinued in the year ended December 31, 2025 due to a strategic realignment; (ii) exclude the items described in Italian payback measure; and (iii) give effect to our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. Pro forma adjusted constant currency revenue growth. This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Pro forma adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends. Note: Pro forma adjusted revenue and pro forma adjusted constant currency revenue growth give effect to, among other things, our acquisition of the Vascular Intervention business from BIOTRONIK SE & Co. KG as if it had occurred on January 1, 2025. The pro forma information is presented for informational purposes only and is not necessarily indicative of the historical results that would have occurred under our ownership and management, nor the results that may be obtained in the future. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 8/6/202622

Adjusted diluted earnings per share. This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vi) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) tax adjustments. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends. Adjusted gross profit and margin. These measures exclude, depending on the period presented, the impacts of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items, and (iii) intangible amortization expense. Adjusted operating profit and margin. These measures exclude, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vi) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) other items. Adjusted selling, general and administrative expenses. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) acquisition, integration and divestiture related items; (iii) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (iv) intangible amortization expense; and (v) other items. Adjusted research and development expenses. This measure excludes the impact of certain costs associated with the registration of medical devices under the European Union Medical Device Regulation. Adjusted income before taxes. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vi) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) other items. Adjusted income tax expense. This measure excludes, depending on the period presented, the impact of (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (v) intangible amortization expense; (vi) tax adjustments; and (vii) other items. Adjusted tax rate. This measure is the percentage of the Company’s adjusted taxes on income from continuing operations to its adjusted income from continuing operations before taxes. Adjusted taxes on income from continuing operations excludes, depending on the period presented, the impact of tax benefits or costs associated with (i) restructuring and optimization charges; (ii) impairment charges; (iii) acquisition, integration and divestiture related items; (iv) separation costs; (v) costs incurred in connection with our implementation of a new global ERP solution and related IT transition costs; (vi) certain costs associated with the registration of medical devices under the European Union Medical Device Regulation; (vii) intangible amortization expense; and (viii) tax adjustments. Non-GAAP Financial Measures TELEFLEX EARNINGS CONFERENCE CALL 8/6/202623

The following is an explanation of certain of the adjustments that are applied with respect to one or more of the non-GAAP financial measures that appear in the presentation to which these appendices are attached: Restructuring and optimization charges - Restructuring and optimization charges include expenses associated with discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies, integrate acquired businesses and optimize product portfolios through targeted optimization efforts. These changes include qualified restructuring costs (which may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement), restructuring related expenses (which may include accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of a restructuring program) and product line exit charges. Impairment charges - Impairment charges, including those related to goodwill, and other assets occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results. Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; temporary financing costs directly associated with the transaction, such as bridge loan financing fees, ticking fees, and similar charges, and the impact of derivative instruments executed to hedge foreign currency exposure or other risks associated with the purchase price. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities. Separation costs - These are expenses related to the Strategic Divestitures, including activities to prepare the businesses for divestiture and maintain continuity through the separation process. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur after the transaction and related transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures have been completed. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 8/6/202624

Italian payback measure - The Italian payback measure is a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a ruling from the Italian courts, we recognized a decrease in our reserves during the year ended December 31, 2024, of which $13.8 million related to prior years when including discontinued operations and $6.2 million on a continuing operations basis. In August 2025, the Italian Parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25% of the amounts originally invoiced for the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve (and corresponding increase to revenue for the year ended December 31, 2025), of which $20.1 million pertains to prior periods when including discontinued operations and $9.0 million on a continuing operations basis. The amounts do not represent normal adjustments to revenue and are nonrecurring in nature, making it difficult to contribute to a meaningful evaluation of our period over period operating performance. Other - These are discrete items that occur sporadically and can affect period-to-period comparisons. MDR - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest- risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD). Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions. ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability. Non-GAAP Adjustments TELEFLEX EARNINGS CONFERENCE CALL 8/6/202625

Six Months Ended June 30, 2026 June 30, 2026 June 29, 2025 % Increase / (Decrease) Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Adjustment Pro Forma Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment Impact Pro Forma Adjusted Constant Currency Revenue Growth Vascular $483.2 $— $483.2 $445.0 $— $445.0 8.6% 2.2% —% 6.4% Interventional1 416.5 — 416.5 214.0 193.0 407.0 94.6% 1.4% 92.3% 0.9% Surgical2 218.9 — 218.9 197.8 (1.0) 196.8 10.7% 1.7% (0.6)% 9.6% Consolidated1 $1,118.6 $— $1,118.6 $856.8 $192.0 $1,048.8 30.6% 1.8% 23.9% 4.9% TELEFLEX EARNINGS CONFERENCE CALL 8/6/202626 Appendix A1 – 2026 Global Product Category Revenue Review Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. (1) Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments (2) Adjustments are inclusive of discontinued product adjustments

Appendix B1 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 8/6/202627 Three Months Ended June 30, 2026 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $570.3 58.2% 37.4% 7.9% 12.8% $45.1 $3.4 7.5% $0.96 Adjustments Restructuring and optimization charges (A) — 0.3 (1.6) — 1.9 10.9 1.9 0.20 Acquisition, integration and divestiture related items (B) — — (1.7) — 1.7 9.9 1.8 0.18 Other (C) — — 3.6 — (3.6) (19.3) (4.0) (0.35) ERP implementation — — (0.7) — 0.7 4.0 0.7 0.08 MDR — — — (0.1) 0.1 0.3 — 0.01 Intangible amortization expense — 3.2 (2.8) — 6.0 34.1 4.6 0.68 Adjustments total — 3.5 (3.2) (0.1) 6.8 39.9 5.0 0.80 Adjusted basis $570.3 61.7% 34.2% 7.8% 19.6% $85.0 $8.4 9.9% $1.76 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

Three Months Ended June 29, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $442.5 60.1% 31.1% 6.0% 20.6% $70.7 $2.5 3.5% $1.54 Adjustments Restructuring and optimization charges (A) — 1.4 — — 1.7 7.4 1.2 0.14 Impairment charges — — — — 1.8 8.1 1.8 0.14 Acquisition, integration and divestiture related items (B) — — 6.4 — (6.4) (27.9) 2.1 (0.68) Separation costs — — — — 0.3 1.3 — 0.03 Other (C) — — — — — 0.1 — — ERP implementation — — (0.9) — 0.9 3.8 0.5 0.07 MDR — — — (0.2) 0.2 0.9 — 0.02 Intangible amortization expense — 3.0 (2.7) — 5.7 25.1 3.0 0.50 Tax adjustments — — — — — — 1.4 (0.03) Adjustments total — 4.4 2.8 (0.2) 4.2 18.8 10.0 0.19 Adjusted basis $442.5 64.5% 33.9% 5.8% 24.8% $89.5 $12.5 14.1% $1.73 TELEFLEX EARNINGS CONFERENCE CALL 8/6/202628 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix B2 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

Appendix B3 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data) TELEFLEX EARNINGS CONFERENCE CALL 8/6/202629 Six Months Ended June 30, 2026 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $1,118.6 57.1% 39.3% 8.0% 8.3% $41.3 $4.4 10.6% $0.84 Adjustments Restructuring and optimization charges (A) — 0.5 (1.5) — 3.5 39.0 6.3 0.73 Acquisition, integration and divestiture related items (B) — 0.7 (1.3) — 1.9 22.9 5.0 0.41 Other items (C) — — 1.8 — (1.8) (19.2) (4.0) (0.35) ERP implementation — — (0.7) — 0.7 7.9 1.3 0.15 MDR — — — (0.1) 0.1 0.7 — 0.02 Intangible amortization expense — 3.2 (2.9) — 6.1 67.9 9.2 1.34 Adjustments total 4.4 (4.6) (0.1) 10.5 119.2 17.8 2.30 Adjusted basis $1,118.6 61.5% 34.7% 7.9% 18.8% $160.5 $22.2 13.8% $3.14 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding.

Six Months Ended June 29, 2025 Revenue Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations GAAP Basis $856.8 60.8% 33.9% 6.0% 19.5% $129.4 $8.9 6.9% $2.67 Adjustments Restructuring and optimization charges (A) — 1.3 — — 1.6 13.5 2.3 0.25 Impairment charges — — — — 0.9 8.1 1.8 0.14 Acquisition, integration and divestiture related items (B) — — 5.4 — (5.4) (46.0) 2.9 (1.07) Separation costs — — — — 0.2 1.3 — 0.03 Other items (C) — — — — — 0.1 — — ERP implementation — — (1.1) — 1.1 9.7 1.5 0.18 MDR — — — (0.2) 0.2 1.6 — 0.03 Intangible amortization expense — 3.1 (2.8) — 5.9 50.7 6.1 0.99 Tax adjustments — — — — — — 2.1 (0.05) Adjustments total 4.4 1.5 (0.2) 4.5 39.0 16.7 0.50 Adjusted basis $856.8 65.2% 35.4% 5.8% 24.0% $168.4 $25.6 15.2% $3.17 TELEFLEX EARNINGS CONFERENCE CALL 8/6/202630 Notes: (1) Selling, general and administrative expenses and research and development expenses are shown as a percentage of net revenues. (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of net revenues. See slide titled Non-GAAP Adjustments included at the beginning of the appendices to this presentation for Non-GAAP definitions. Totals may not sum due to rounding. Appendix B4 – Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

TELEFLEX EARNINGS CONFERENCE CALL 8/6/202631 A. Restructuring and optimization charges – For the three months ended June 30, 2026, pre-tax restructuring charges were $0.2 million and restructuring related charges were $10.6 million. For the three months ended June 29, 2025, pre-tax restructuring charges were $1.3 million, restructuring related charges were $3.5 million, and product optimization charges were $2.6 million. For the six months ended June 30, 2026, pre-tax restructuring charges were $17.1 million and restructuring related charges were $21.9 million, partially offset by a benefit from product rationalization charges of $0.1 million. For the six months ended June 29, 2025, pre-tax restructuring charges were $2.7 million, restructuring related charges were $8.2 million, and product optimization charges were $2.6 million. B. Acquisition, integration and divestiture related items – For the three and six months ended June 30, 2026, these charges primarily related to the acquisition of the Vascular Intervention business of BIOTRONIK SE & Co. KG. For the three months ended June 30, 2026 these charges included acquisition and integration costs of $8.9 million. For the six months ended June 30, 2026 these charges included acquisition and integration costs of $16.7 million and inventory step up costs of $8.0 million. For the three and six months ended June 29, 2025, these charges primarily related to the acquisition the Vascular Intervention business of BIOTRONIK SE & Co. KG and changes in the estimated fair value of our contingent consideration liabilities. For the three months ended June 29, 2025 the charges included acquisition and integration costs of $15.8 million, which were offset by a benefit of $59.7 million related to non-designated foreign currency forward contracts. For the six months ended June 29, 2025 the charges included acquisition and integration costs of $22.1 million, which were offset by a benefit of $82.2 million related to non-designated foreign currency forward contracts. C. Other – For the three and six months ended June 30, 2026, other items included a benefit from a litigation settlement of $25.0 million partially offset by legal and advisory fees incurred in response to an activist investor campaign of $3.6 million, a loss on extinguishment of debt of $1.2 million, and charges incurred in connection with the credit agreement refinancing of $1.0 million. For the three and six months ended June 29, 2025, other items included expenses associated with prior year tax matters. Appendix B Tickmarks

Appendix C - 2026 Adj. Operating Margin Guidance Reconciliation TELEFLEX EARNINGS CONFERENCE CALL 8/6/202632 Forecasted GAAP Operating Margin 9.4% Estimated restructuring and optimization items 2.2% Estimated acquisition, integration and divestiture related items 1.8% Estimated other items (1.2)% Estimated ERP implementation 0.7% Estimated intangible amortization expense 6.1% Forecasted Adjusted Operating Margin 19.0%

Appendix D - Reconciliation of Forecasted 2026 Adjusted Earnings Per Share Guidance TELEFLEX EARNINGS CONFERENCE CALL 8/6/202633 Low High Forecasted GAAP Diluted Earnings Per Share from continuing operations $2.54 $2.84 Restructuring and optimization items, net of tax $0.98 $0.98 Acquisition, integration and divestiture related items, net of tax $0.73 $0.73 Other costs, net of tax $(0.42) $(0.42) ERP implementation, net of tax $0.31 $0.31 MDR, net of tax $0.02 $0.02 Intangible amortization expense, net of tax $2.74 $2.74 Forecasted Adjusted Diluted Earnings Per Share from continuing operations, net of tax $6.90 $7.20

2026 Financial Review - Six Months Ended June 30, 2026 TELEFLEX EARNINGS CONFERENCE CALL 8/6/202634 Gross margin Operating margin Effective tax rate Earnings per share ◦ Adjusted gross margin of 61.5%, down 370 bps year-over-year ◦ GAAP gross margin of 57.1% vs. 60.8% in the prior year period ◦ Adjusted operating margin of 18.8%, down 520 bps year-over-year ◦ GAAP operating margin of 8.3% vs. 19.5% in prior year period ◦ Adjusted tax rate of 13.8% vs. 15.2% in prior year period ◦ GAAP tax rate of 10.6% vs. 6.9% in prior year period ◦ Adjusted EPS of $3.14, down 0.9% year-over-year ◦ GAAP EPS of $0.84 vs. $2.67 in prior year period Global revenue growth ◦ Pro Forma adjusted revenue increased 4.9% year-over-year on a constant currency basis ◦ Revenue increased 30.6% year-over-year on a GAAP basis Note: See appendices for reconciliations of non-GAAP financial information.

Rx Only INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR EZPLAZ™ FREEZE DRIED PLASMA INDICATIONS EZPLAZ™ Freeze Dried Plasma (FDP) is indicated for transfusion in adults when plasma is required and other plasma products are not available. Indications include: • Management of preoperative or bleeding patients who require replacement of multiple plasma coagulation factors [e.g., liver disease, disseminated intravascular coagulation (DIC)] • Patients undergoing massive transfusion who have clinically significant coagulation deficiencies • Patients taking warfarin who are bleeding or need to undergo an invasive procedure before vitamin K could reverse the warfarin effect or who need only transient reversal of warfarin effect IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Do not use EZPLAZ™ FDP: • In patients with history of hypersensitivity to fresh frozen plasma (FFP), liquid plasma or to plasma-derived products including any plasma proteins • In patients with IgA deficiency WARNINGS AND PRECAUTIONS As with other licensed blood products, EZPLAZ™ FDP may cause adverse events known to be associated with transfusion of blood products. For a complete list and further details not provided below, please refer to the Circular of Information. Hemolytic Transfusion Reactions Hemolytic transfusion reactions can occur with ABO blood group mismatches. EZPLAZ™ FDP is provided in blood group type AB or type A low titer Anti-B (< 1:200 by saline tube method). Transfusion-Related Acute Lung Injury (TRALI) To mitigate the risk of TRALI, EZPLAZ™ FDP is manufactured from FFP donated by male only donors. Infection Risk from Human Plasma Because EZPLAZ™ FDP is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, bacteria, and theoretically the variant Creutzfeldt-Jakob disease (vCJD) agent. Hypersensitivity Reaction Hypersensitivity reactions, including anaphylaxis, may occur. Discontinue the transfusion if signs or symptoms of hypersensitivity occur and treat appropriately. Specific Therapies EZPLAZ™ FDP may be less effective in correcting certain coagulopathies when therapies targeting specific coagulation factor deficiencies or anticoagulant effects are available. In such situations, clinicians should consider the use of targeted therapies, when clinically appropriate, including vitamin K for urgent vitamin K antagonist reversal, fibrinogen-containing products for hypofibrinogenemia, specific coagulation factor concentrates, or specific reversal agents for non-vitamin K antagonist anticoagulants. Selection of therapy should be based on the patient’s clinical condition, urgency of correction, and availability of alternative treatments. Volume Expansion EZPLAZ™ FDP is not intended for routine volume expansion. When administered in the absence of a documented coagulation factor deficiency or plasma protein deficiency, the expected clinical benefit may be limited, and alternative volume expanders are generally more appropriate. Clinicians should consider alternative therapies based on the patient’s clinical needs. Elevated INR Transfusion of EZPLAZ™ FDP may not result in meaningful correction of a minimally elevated international normalized ratio (INR), such as values between 1.5 and 1.7. In these situations, the likelihood of achieving clinically significant hemostatic benefit may be low, and alternative management strategies should be considered based on the patient’s overall clinical condition. ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Teleflex at 1-866-246-6990 and FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For additional Safety Information, please see Full Prescribing Information at www.teleflex.com/EZPLAZPI. TELEFLEX EARNINGS CONFERENCE CALL 8/6/202635

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 EX-99.1 422.3 KB
• EX-99.2 EX-99.2 58.3 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB